TLCK Activators
Thrombin-Like Enzyme Cleaving Kinase (TLCK) activators encompass a range of chemical compounds that indirectly augment TLCK's functional activity, predominantly within coagulation pathways. Benzamidine and Gabexate, as serine protease inhibitors, enhance TLCK's activity by mitigating the competitive inhibition posed by other serine proteases. This results in an increased availability of substrates for TLCK, enhancing its role in coagulation. Similarly, Argatroban and Bivalirudin, by inhibiting thrombin, alleviate the competition for substrates between thrombin and TLCK, indirectly boosting TLCK's efficiency. The direct thrombin inhibitors, D-Phe-Pro-Arg chloromethyl ketone and Dabigatran, function along the same lines, ensuring that TLCK has unimpeded access to its substrates. Nafamostat contributes to this dynamic by broadly inhibiting serine proteases, thereby reducing the overall proteolytic processing that competes with TLCK's action. These mechanisms collectively ensure that TLCK's functional capacity in proteolytic processes, especially in coagulation, is maximized.
Further enhancing TLCK activity, compounds like Apixaban, Edoxaban, and Rivaroxaban, which are Factor Xa inhibitors, indirectly promote TLCK activity by diminishing Factor Xa's competitive processing of substrates that are also targets of TLCK. This indirect enhancement enables TLCK to function more efficiently within the coagulation cascade. Fondaparinux, though an indirect Factor Xa inhibitor, similarly aids in boosting TLCK activity by reducing thrombin generation, which is a downstream effect of Factor Xa inhibition. Warfarin, by antagonizing Vitamin K, leads to a decrease in the synthesis of functional clotting factors, including thrombin. This reduction in thrombin levels further alleviates the competitive substrate processing between thrombin and TLCK, enhancing TLCK's role in coagulation processes. Collectively, these TLCK activators, through their targeted influence on coagulation pathway components, facilitate an enhanced functional capacity of TLCK without necessitating direct activation or upregulation of its expression.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Benzamidine | 618-39-3 | sc-233933 | 10 g | $292.00 | 1 | |
Benzamidine, a serine protease inhibitor, indirectly enhances TLCK activity by inhibiting competitive serine proteases. This action leads to a relative increase in TLCK functionality as its substrates are less likely to be processed by other enzymes. | ||||||
Argatroban | 74863-84-6 | sc-201310 sc-201310A | 10 mg 50 mg | $117.00 $469.00 | 13 | |
Argatroban, a direct thrombin inhibitor, augments TLCK activity by reducing thrombin's competitive interaction with TLCK's substrates, thus indirectly enhancing TLCK's functional role in coagulation and related pathways. | ||||||
Nafamostat mesylate | 82956-11-4 | sc-201307 sc-201307A | 10 mg 50 mg | $82.00 $306.00 | 4 | |
Nafamostat, acting as a broad-spectrum serine protease inhibitor, indirectly enhances TLCK activity by reducing the proteolytic processing of substrates common to TLCK, thereby indirectly augmenting TLCK's functional capacity in proteolytic pathways. | ||||||
Gabexate mesylate | 56974-61-9 | sc-215066 | 5 mg | $100.00 | ||
Gabexate, a serine protease inhibitor, enhances TLCK's activity by decreasing the activity of competitive serine proteases. This relative increase in TLCK activity is due to the reduced competition for substrate molecules. | ||||||
Apixaban | 503612-47-3 | sc-364406 sc-364406A | 10 mg 50 mg | $240.00 $634.00 | 2 | |
Apixaban, an inhibitor of Factor Xa, indirectly enhances TLCK activity in coagulation by reducing the functional competition between Factor Xa and TLCK for similar substrates, thus allowing TLCK to act more freely on its target molecules in coagulation pathways. | ||||||
Edoxaban | 480449-70-5 | sc-483508 | 25 mg | $522.00 | ||
Edoxaban, another Factor Xa inhibitor, similarly augments TLCK activity by decreasing Factor Xa-mediated reactions. This reduction in Factor Xa activity indirectly enhances TLCK's functional capacity in coagulation pathways by reducing substrate competition. | ||||||
Rivaroxaban | 366789-02-8 | sc-208311 | 2 mg | $158.00 | 18 | |
Rivaroxaban acts as a Factor Xa inhibitor, indirectly increasing TLCK activity by reducing competition for substrates within the coagulation cascade, thereby indirectly facilitating TLCK's functional role. | ||||||
Bivalirudin | 128270-60-0 | sc-278793 | 5 mg | $110.00 | ||
Bivalirudin, a direct thrombin inhibitor, indirectly enhances TLCK functionality by inhibiting thrombin, thus reducing its competition with TLCK for substrates in coagulation pathways and allowing TLCK to act more efficiently on its substrates. | ||||||
Fondaparinux | 104993-28-4 | sc-507424 | 10 mg | $297.00 | ||
Fondaparinux, an indirect Factor Xa inhibitor, enhances TLCK activity by reducing the generation of thrombin, thereby decreasing competition for TLCK's substrates and indirectly increasing TLCK's functional capacity in the coagulation cascade. | ||||||
Warfarin | 81-81-2 | sc-205888 sc-205888A | 1 g 10 g | $73.00 $246.00 | 7 | |
Warfarin, a Vitamin K antagonist, indirectly enhances TLCK activity by reducing the synthesis of functional clotting factors, including thrombin. This reduction in thrombin levels indirectly boosts TLCK's role in coagulation by lessening substrate competition. | ||||||